IPR
Topic 61 Comparative Patent
Topic 61 — Comparative Patent Laws: UK, US, EU, Japan, India
Patent law is among the most internationally harmonised areas of intellectual property — the Paris Convention (1883), the PCT (1970), and the TRIPS Agreement (1995) establish minimum standards binding all major jurisdictions. Yet the operational details differ substantially. The US Patent Act (35 USC) reflects a "first-to-invent" tradition that shifted to "first-inventor-to-file" only in 2013 (America Invents Act). The UK Patents Act 1977 implements the European Patent Convention 1973. The EU operates through the European Patent Office (granting bundles of national patents) and the new Unitary Patent System (effective 1 June 2023, providing single patents valid across participating EU states). Japan's Patent Act follows a distinctive examination tradition with strong utility model protection. India's Patents Act 1970, post-2005 amendments, balances first-to-file principles with strong public-interest safeguards (Section 3(d), compulsory licensing). This topic provides a comprehensive side-by-side comparison.
1. The Five Statutes — Master Comparison
Feature | UK | US | EU | Japan | India |
|---|---|---|---|---|---|
Principal Statute | Patents Act 1977 | 35 USC §§ 1 et seq. | European Patent Convention 1973 + Unitary Patent Regulation | Patent Act 1959 (as amended) | Patents Act 1970 (as amended 2005) |
Major Reform | EU TM/PT directives transposed | America Invents Act 2011 (effective 16 March 2013) | Unitary Patent System (1 June 2023) | Continuous reforms; Strategic Innovation Promotion Strategy 2025 | 2005 Amendment (product patents + Section 3(d)) |
Patent Office | UK Intellectual Property Office (UKIPO) | United States Patent and Trademark Office (USPTO) | European Patent Office (EPO) — Munich, The Hague, Berlin | Japan Patent Office (JPO) | Indian Patent Office (CGPDTM) |
Number of patents granted (2024 approx.) | ~7,000 | ~340,000 | ~104,000 | ~190,000 | ~44,000 |
First-to-File / First-to-Invent | First-to-file | First-inventor-to-file (since 2013) | First-to-file | First-to-file | First-to-file |
2. Substantive Patentability
Requirement | UK | US | EU | Japan | India |
|---|---|---|---|---|---|
Novelty | Absolute | Absolute (post-AIA 2013) | Absolute | Absolute | Absolute |
Inventive step | Yes — Pozzoli test | Yes — Graham factors / KSR (2007) | Yes — problem-solution approach | Yes — characteristics of skilled person | Yes — Section 2(1)(ja); Bishwanath Prasad standard |
Industrial application / Utility | Industrial application | Utility (lower threshold) | Industrial application | Industrial applicability | Industrial application |
Excluded subject matter | Section 1(2) — software, business methods, mathematical methods | 35 USC § 101 — abstract ideas, natural phenomena, laws of nature (Alice 2014) | Article 52(2) EPC — software per se, mathematical methods, business methods | Section 32 — abstract methods, methods of medical treatment | Section 3 — 16 categories; Section 3(d) anti-evergreening unique |
Methods of medical treatment | Section 4A — excluded | Allowed (rare exception) | Article 53(c) EPC — excluded | Section 32(1) — excluded | Section 3(i) — excluded |
Pharmaceutical second use | Limited (Swiss-style claims) | Allowed (with restrictions) | Allowed (Eisai-style claims) | Allowed | Limited (Section 3(d) constraint) |
Software patents | Restrictive (technical effect required) | Restrictive post-Alice (2014) | Restrictive — technical character required | Permissive | Restrictive — Section 3(k) computer programs per se |
Anti-evergreening | No specific provision | No specific provision | No specific provision | No specific provision | Section 3(d) — UNIQUE; therapeutic efficacy required |
✅ Section 3(d) — India's globally distinctive innovation India's Section 3(d) anti-evergreening provision is unique among major patent jurisdictions. No other major patent system contains an explicit provision excluding new forms of known substances unless they demonstrate enhanced therapeutic efficacy. The provision has been imitated in some developing countries (Argentina, Philippines, South Africa's draft policy) but the major patent jurisdictions (US, UK, EU, Japan) rely on inventive step alone to filter out trivial pharmaceutical modifications. Section 3(d) provides a sharper, more predictable filter — and a stronger generic-friendly framework. |
3. Patent Term and Renewal
Feature | UK | US | EU | Japan | India |
|---|---|---|---|---|---|
Standard term | 20 years from filing | 20 years from filing (or earliest priority) | 20 years from filing (national patents) | 20 years from filing | 20 years from filing |
Patent term extension (PTE) | Up to 5 years for SPC (pharma) | Up to 5 years (35 USC § 156) | Up to 5 years SPC | Up to 5 years | NOT available |
Patent term adjustment | No | Yes — for USPTO delays (35 USC § 154) | No | No | No |
Annual renewal fees | Yes — increasing scale | Maintenance fees at 3.5, 7.5, 11.5 years | Yes (national) | Yes — annual | Yes — increasing scale |
Restoration of lapsed | Yes — within 19 months | Yes — within 24 months | Variable by member state | Yes — within 6 months grace + restoration | Yes — within 18 months (Section 60) |
✅ No PTE in India — strategic implication India does NOT provide patent term extension for pharmaceutical regulatory delays — a stark contrast with US (Hatch-Waxman 1984), EU (SPC Regulation 1992) and Japan. The 20-year term runs strictly from the filing date, regardless of how long marketing approval takes. This means: · Foreign pharma companies often face shorter effective monopoly in India compared to home markets. · Indian generic launches can occur 5+ years earlier than corresponding launches in markets with PTE. · The absence of PTE is a deliberate policy choice — supporting generic-friendly access to medicines. The issue is occasionally raised in policy debates but has not been adopted in legislation. |
4. Application Procedure
Stage | UK | US | EU | Japan | India |
|---|---|---|---|---|---|
Filing requirements | Standard PCT/Paris | Standard PCT/Paris | EPC requirements; 38 contracting states | Standard PCT/Paris | Form 1 + Form 2 + Form 3 (Section 8) |
Provisional applications | Yes | Yes | No (only complete) | Yes | Yes (Section 9) |
Examination request | Within 4 years from priority | Automatic on filing | Within 6 months of search report | Within 3 years from filing | Within 48 months from priority/filing (Section 11B) |
Average examination time | ~3-4 years | ~2-3 years | ~3-5 years | ~9-12 months (with PPH) | ~3-5 years |
Average filing fee (basic) | £60 | $320 (large entity) | €125 (online) | ¥14,000 | ₹1,600 (online) |
Pre-grant opposition | No | No (third-party prior art submissions) | Yes (post-grant only) | No | Yes — Section 25(1) ANY person |
Post-grant opposition | Yes — within 9 months of grant | No | Yes — within 9 months | Yes — within 6 months | Yes — Section 25(2) within 12 months |
5. Enforcement and Remedies
Feature | UK | US | EU | Japan | India |
|---|---|---|---|---|---|
Forum for infringement | High Court Patents Court | US District Court (often E.D. Texas) | National courts; Unified Patent Court (UPC) since 2023 | Tokyo / Osaka District Court IP Division | High Court IPD (post-2021) |
Damages | Compensatory + lost royalty | Compensatory + reasonable royalty + treble for wilful | Variable by member state | Compensatory + reasonable royalty | Compensatory + reasonable royalty + punitive (Time Inc./Cartier framework) |
Injunctions | Standard equitable | Discretionary post-eBay v. MercExchange (2006) | Standard equitable | Standard | Three-prong test + public interest factor (Roche v. Cipla 2008) |
Compulsory licensing | Available (rarely used) | Government-use only (28 USC 1498) | Available (rarely used) | Available | Section 84-92A — Bayer-Natco 2012 only grant |
Pre-grant opposition by public | No | No | No | No | YES — distinctive Indian feature |
Working requirement | No | No | No | No | YES — Section 83 + Form 27 |
6. International Filing Systems
A. PCT Membership Dates
- UK — 24 January 1978.
- US — 24 January 1978.
- Japan — 1 October 1978.
- European Patent Convention — 7 October 1977 (in force).
- India — 7 December 1998.
B. EU Unitary Patent System (since 1 June 2023)
The Unitary Patent System represents a major recent development in EU patent law. Key features:
- Single patent valid across participating EU states (currently 17 of 27 member states; expanding).
- Single annual renewal fee covering all participating states.
- Unified Patent Court (UPC) handles infringement and validity actions.
- Cost savings — typically 15-30% compared to national patent route in EU.
- First UPC infringement decision (UPC, Düsseldorf Local Division, 26 October 2023) established the operational framework.
✅ Implications for Indian patent owners The Unitary Patent System changes the calculus for Indian companies seeking European protection: · Single application + single fee = streamlined access. · Single court for litigation = faster resolution. · Risk: single revocation can cascade across all participating states. Indian patent strategy now typically includes: file in India + PCT international application + EU Unitary Patent + selective national filings in non-EU countries (UK post-Brexit, Switzerland, Norway). |
7. Distinctive Features by Jurisdiction
A. UK — Brexit Impact
Post-Brexit (1 January 2021), the UK left the EU patent system. Key implications:
- UK is NOT participating in the EU Unitary Patent System (despite ratification of UPC Agreement before Brexit).
- UK national patents remain available through UKIPO.
- European Patents (granted by EPO) still validate in UK separately.
- SPC (pharmaceutical patent extension) regime continues but is now UK-only.
B. US — America Invents Act 2011
The America Invents Act (AIA), effective 16 March 2013, transformed US patent law:
- Shifted from "first-to-invent" to "first-inventor-to-file".
- Created Inter Partes Review (IPR) and Post-Grant Review (PGR) procedures before USPTO Patent Trial and Appeal Board.
- Allows third parties to challenge patents quickly and cheaply.
- Expanded prior user rights.
C. EU — Unitary Patent and UPC
The Unitary Patent System (operative since 1 June 2023) is the most significant European patent reform in 50 years:
- 17 EU member states currently participating; expanding.
- UPC headquarters Luxembourg; central divisions Paris, Munich, Milan.
- Local and regional divisions across participating states.
- English, French, German official languages with translation arrangements.
D. Japan — Patent Prosecution Highway (PPH)
Japan pioneered the Patent Prosecution Highway — bilateral arrangements that allow accelerated examination based on positive results in another jurisdiction. Japan has PPH agreements with all major patent offices including India (since 21 November 2019). Indian applicants whose Indian patent has been granted can request accelerated Japanese examination based on the Indian decision.
E. India — Distinctive Innovations
India's patent law has developed several distinctive features:
- Section 3(d) anti-evergreening — globally unique and influential.
- Pre-grant opposition open to "any person" — strongest public participation framework.
- Active compulsory licensing framework (Sections 84-92A).
- Working requirement with Form 27 disclosure.
- No patent term extension — generic-friendly approach.
8. Strategic Implications for Indian Patent Owners
✅ Twelve cross-jurisdictional strategy points Calendar PCT 31-month national phase deadline carefully — varies by jurisdiction (US 30 months, India 31 months). For pharma, file in India early — no PTE means effective monopoly is shorter than in US/EU. Adapt claims for Indian Section 3 considerations during PCT national phase entry — Section 3(d), 3(j), 3(k). For US, draft for Alice (2014) computer-implemented inventions — technical effect required. For EU, consider Unitary Patent for streamlined enforcement; assess single-revocation risk. For UK post-Brexit, plan separate UK national filing alongside EPO. For Japan, leverage PPH for accelerated examination based on Indian grant. For US AIA Inter Partes Review challenges, prepare validity defence early. For Indian post-grant opposition, calendar 12-month window strictly. For pre-grant opposition (Indian unique feature), consider strategic interventions during examination. For working compliance, maintain Form 27 records — Indian-only requirement. For multi-jurisdictional litigation, coordinate strategy across forums; potential parallel proceedings. |
🎯 EXAM POINTERS — TOPIC 61
|